PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, non-randomized, phase2 trial to evaluate efficacy and
safety of SHR-1210 in patients with relapsed or refractory classic Hodgkin's lymphoma. The
primary objective is to assess ORR of SHR-1210 in patients with relapsed or refractory
classic Hodgkin's lymphoma.